Lifestyle can shape the composition of beneficial bacteria and other microorganisms within the mouth, according to a new study led by Penn State biologists.
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) – Psychedelic Alpha
Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia DMX-1002 (Ibogaine)